Ignite Creation Date:
2024-05-06 @ 8:17 PM
Last Modification Date:
2024-10-26 @ 3:24 PM
Study NCT ID:
NCT06325267
Status:
RECRUITING
Last Update Posted:
2024-03-27
First Post:
2024-03-15
Brief Title:
Clinical Characteristics of Primary Liver Cancer
Sponsor:
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Organization:
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Study Overview
Official Title:
A Single Center Retrospective Clinical Study on the Clinical Characteristics of Primary Liver Cancer
Status:
RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Primary liver cancer PLC is the sixth most common malignancy in the world and the third most common cause of malignancy death In 2020 there were about 905677 new cases of PLC worldwide and 830180 deaths Despite the availability of a variety of treatments for PLC the 5-year net survival rate is still only 5 to 30 How to effectively reduce the disease burden of PLC is a major public health problem that needs to be solved worldwide The clinical characteristics and prognosis of PLC caused by different pathogenic factors are different Therefore it is of great significance to fully identify the risk factors of PLC be familiar with the clinical characteristics and prognosis of disease development and understand the relevant monitoring and follow-up strategies for the prevention and treatment of PLC
Detailed Description:
Primary liver cancer PLC is the sixth most common malignancy in the world and the third most common cause of malignancy death PLC mainly includes hepatocellular carcinoma 75-85 and intrahepatic cholangiocarcinoma 10-15 In 2020 there were about 905677 new cases of PLC worldwide and 830180 deaths Despite the availability of a variety of treatments for PLC the 5-year net survival rate is still only 5 to 30 How to effectively reduce the disease burden of PLC is a major public health problem that needs to be solved worldwide Common risk factors for PLC include Hepatitis B virus HBV Hepatitis C virus HCV infection alcohol consumption metabolic factors etc Although antiviral drugs can control or even cure chronic HBV and HCV to a certain extent chronic viral infection is still the leading cause of PLC worldwide In addition with the prevalence of obesity diabetes and non-alcoholic fatty liver disease NAFLD the incidence of non-infectious PLC is gradually increasing In recent years NAFLD has gradually become the leading cause of liver transplant waiting list for patients with hepatocellular carcinoma in the United States The clinical characteristics and prognosis of PLC caused by different pathogenic factors are different Therefore it is of great significance to fully identify the risk factors of PLC be familiar with the clinical characteristics and prognosis of disease development and understand the relevant monitoring and follow-up strategies for the prevention and treatment of PLC Currently there are few large single-center cohort studies on the clinical features and long-term prognosis of PLC
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None